Trials / Active Not Recruiting
Active Not RecruitingNCT06701526
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications
Interventional, Open-label Trial, Investigating the Effectiveness of Eptinezumab in Participants With Migraine and Previous Inadequate Response to CGRP-targeting Therapies
- Status
- Active Not Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 150 (actual)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The main goal of this trial is to learn whether eptinezumab improves migraine symptoms and quality of life of participants with migraine who did not perceive a sufficient improvement during previous treatment with therapies targeting calcitonin gene-related peptide (CGRP).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eptinezumab | Solution for infusion |
Timeline
- Start date
- 2024-12-18
- Primary completion
- 2026-06-05
- Completion
- 2026-06-05
- First posted
- 2024-11-22
- Last updated
- 2026-03-09
Locations
28 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06701526. Inclusion in this directory is not an endorsement.